Malaysian health supplement maker DXN explores sale at $1b valuation

Capsules containing a blend of ginkgo biloba, ginseng and saffron extracts, called Sailuotong or SLT, are displayed for a photograph at the China Academy of Chinese Medical Sciences' Xiyuan Hospital in Beijing, China, on Tuesday, Sept. 25, 2018. Photographer: Giulia Marchi/Bloomberg

DXN Holdings Bhd.’s owners are exploring a sale of the Malaysian health supplement producer, in a deal that could value the firm at as much as $1 billion including debt, people with knowledge of the matter said.

Continue reading this story with a subscription to DealStreetAsia.


Contact us for corporate subscriptions at